Antivirals Market Report 2026

The antivirals market size has grown strongly in recent years. It will grow from $114.4 billion in 2025 to $122.08 billion in 2026 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to global viral outbreaks, hiv and hepatitis burden, government antiviral stockpiling, availability of generics, expansion of infectious disease programs.

The antivirals market size is expected to see strong growth in the next few years. It will grow to $163.33 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to emerging viral threats, investment in antiviral r&d, increased vaccination and treatment integration, global health initiatives, demand for rapid-response therapeutics. Major trends in the forecast period include rising demand for broad-spectrum antivirals, growing focus on pandemic preparedness, expansion of generic antiviral drugs, increased use in chronic viral infections, development of novel mechanism antivirals.

The rising incidence of influenza is expected to drive the growth of the antiviral market in the coming years. Influenza, commonly known as the flu, is a highly contagious viral respiratory infection that affects the nose, throat, and lungs. The increasing prevalence of influenza is mainly attributed to colder weather and indoor crowding, which allow the virus to survive longer and promote person-to-person transmission in close proximity. Antivirals are employed for the treatment of influenza and work by inhibiting the replication and spread of influenza viruses within the body. For example, in November 2024, the Centers for Disease Control and Prevention, a US-based national public health agency, reported that the 2023 to 2024 influenza season was estimated to result in 40 million illnesses, 18 million medical visits, 470,000 hospitalizations, and 28,000 deaths. Consequently, the growing incidence of influenza is propelling the expansion of the antiviral market.

Major companies operating in the antiviral market are concentrating on developing innovative therapies such as oral antiviral treatments to enhance patient adherence, improve accessibility, lower healthcare expenses, and offer more convenient and effective solutions for managing viral infections. Oral antiviral treatments are medications administered orally to combat viral infections. These treatments function by preventing viruses from replicating or spreading within the body, thereby helping to lessen the severity and duration of the infection. For example, in May 2023, Pfizer, a US-based pharmaceutical company, announced the approval of Paxlovid, making it the first oral antiviral treatment for COVID-19 in adults authorized by the Food and Drug Administration, a US government agency. This approval is particularly noteworthy as it introduces a new therapeutic option for managing COVID-19, especially as the pandemic is shifting toward an endemic stage. Paxlovid is specifically intended for adults with mild-to-moderate COVID-19 who are at high risk of progressing to severe disease, including hospitalization or death.

Major companies in the antiviral market are concentrating on creating advanced therapeutic solutions, including antiviral treatments, to improve patient outcomes and limit viral transmission. Antiviral treatments play a crucial role in managing viral infections and preventing complications in affected individuals. For example, in August 2024, Red Queen’s Technology, a US-based pharmaceutical company, introduced versatile antivirals. Apple Tree Partners invested $55 million in Red Queen Therapeutics, a biotech firm working on broad-spectrum antiviral treatments. The company focuses on infectious pathogens such as COVID-19 and influenza, having already advanced a COVID antiviral through Phase 1 trials and received U.S. government funding for a pan-influenza drug. Co-founded by Harvard professor Loren Walensky, Red Queen utilizes stapled lipopeptides to inhibit viral fusion and block viral entry into cells.

Major companies operating in the antivirals market are AbbVie Inc., Bristol-Myers-Squibb Co., Chemical Industrial & Pharmaceutical Laboratories Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson Services Ltd., Merck & Co. Inc., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Abbott Laboratories, Schering-Plough Corporation, Pfizer Inc., Sanofi-Synthélabo Ltd., Inovio Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., AVI Biopharma International Ltd., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Biogen Inc., Genentech USA Inc., Vertex Pharmaceuticals Inc.

North America was the largest region in the anti-viral drug therapy market in 2025. The Middle East is expected to be the fastest-growing region in the antivirals market during the forecast period. The regions covered in the antivirals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antivirals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have disrupted antiviral api supply chains by increasing the cost of imported active pharmaceutical ingredients and key synthesis intermediates used in drug manufacturing. These impacts are most evident in Asia and North America, where antiviral production depends on cross border sourcing networks. Rising tariff related costs have contributed to supply volatility and pricing pressure across antiviral therapies. This has influenced procurement planning and inventory management for public health programs and pharmaceutical companies. However, tariffs are also accelerating domestic antiviral manufacturing capabilities, local api production, and improved supply chain resilience over the long term.

The antivirals market research report is one of a series of new reports that provides antivirals market statistics, including antivirals industry global market size, regional shares, competitors with a antivirals market share, detailed antivirals market segments, market trends and opportunities, and any further data you may need to thrive in the antivirals industry. This antivirals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Antivirals are drugs created to manage viral infections by blocking the replication of viruses inside the host's cells. Unlike antibiotics, which act against bacteria, antivirals are specifically intended to fight viruses such as influenza, HIV, or hepatitis. They function by disrupting different stages of a virus's lifecycle, aiding in the reduction of both the severity and duration of an infection.

The main categories of antiviral drug therapy are branded and generic. The different drug classes included are DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, neuraminidase inhibitors, and others that are used for HIV, hepatitis, herpes, influenza, and additional viral infections. Reverse transcriptase inhibitors (RTIs) are a class of antiretroviral drugs used to manage HIV infection or AIDS, and in some instances, hepatitis B.

The anti-viralsmarket consists of sales of amantadine and rimantadine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.